DNA lesions trigger the DNA damage response (DDR) machinery, which protects genomic integrity and sustains cellular survival. Increasing data underline the significance of the integrity of the DDR pathway in chemotherapy response. According to a recent work, persistent exposure of A549 lung carcinoma cells to doxorubicin induces an initial DDR-dependent checkpoint response, followed by a later DDR-independent, but p27(Kip1)-dependent one. Prompted by the above report and to better understand the involvement of the DDR signaling after chemotherapeutic stress, we examined the potential role of the canonical DDR pathway in A549 cells treated with doxorubicin. Exposure of A549 cells, prior to doxorubicin treatment, to ATM, ATR and DNA-PKcs inhibitors either alone or in various combinations, revealed that the earlier documented two-step response was DDR-dependent in both steps. Notably, inhibition of both ATM and ATR or selective inhibition of ATM or DNA-PKcs resulted in cell-cycle re-entry despite the increased levels of p27(Kip1) at all time points analyzed. We further investigated the regulation of p27(Kip1) protein levels in the particular setting. Our results showed that the protein status of p27(Kip1) is mainly determined by p38-MAPK, whereas the role of SKP2 is less significant in the doxoroubicin-treated A549 cells. Cumulatively, we provide evidence that the DNA damage signaling is responsible for the prolonged cell cycle arrest observed after persistent chemotherapy-induced genotoxic stress. In conclusion, precise identification of the molecular mechanisms that are activated during the chemotherapeutic cycles could potentially increase the sensitization to the therapy applied.

Centre for Genotoxic Stress Research Danish Cancer SocietyCopenhagen Denmark; Laboratory of genome integrity Institute of Molecular and Translational Medicine Palacky UniverzityOlomouc Czech Republic

Department of Biological Chemistry School of Medicine University of Athens Athens Greece

Molecular Carcinogenesis Group Laboratory of Histology Embryology School of Medicine University of Athens Greece

See more in PubMed

Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8. PubMed PMC

Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–5. PubMed

Cuadrado M, Gutierrez-Martinez P, Swat A, et al. p27kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. Cancer Res. 2009;69:8726–32. PubMed PMC

Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;15:1895–909. PubMed PMC

Carrano AC, Eytan E, Hershko A, et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1999;1:193–9. PubMed

Sutterlüty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol. 1999;1:207–14. PubMed

Tsvetkov LM, Yeh KH, Lee SJ, et al. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Curr. Biol. 1999;9:661–4. PubMed

Pateras IS, Apostolopoulou K, Koutsami K, et al. Downregulation of the KIP family members p27KIP1 and p57KIP2 by SKP2 and the role of methylation in p57KIP2 inactivation in non small cell lung cancer. Int J Cancer. 2006;119:2546–56. PubMed

Sugihara E, Kanai M, Saito S, et al. Suppression of centrosome amplification after DNA damage depends on p27 accumulation. Cancer Res. 2006;66:4020–9. PubMed

Bar-On O, Shapira M, Hershko DD. Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cells. Anti-Cancer Drugs. 2007;18:1113–21. PubMed